Median Technologies receives the Forbes 2018 Futur40 award and special recognition prize for the “Health-Life Sciences” company category

Sophia Antipolis, France

Press release – For immediate release – 5:45 pm CEST

Median Technologies, The Imaging Phenomics Company®, announces that on July 11, it received the 2018 Futur40 award and special recognition prize in the category “Health-Life Sciences”. These prizes are awarded by Forbes, PMEFinance-EuropeEntrepreneurs and their partners Euronext, MorningStar, RSM, F2iC and Paris Europlace to distinguish French champions of growth.

“We are very proud to receive the Futur40 award and this special recognition in Health and Life Sciences”, said Fredrik Brag, CEO of Median Technologies. “These awards highlight the importance of SMEs and MidCaps in the Paris international financial center. Median received the Futur40 award in 2017 and it’s an honor to be back in the charts for this year”, he added.

The Futur40 ranking is based on data provided by Morningstar and highlights the 40 Paris-listed companies that have distinguished themselves based on their financial performance and the originality of their business model. The criteria for winning the Futur40 award are as follows:

  • Cumulative sales growth of more than 15% over the last three fiscal years,
  • € 5 million of minimum turnover, and
  • The company is listed in Paris, with a minimum stock footprint (free float, trading volumes) to have certified public data.

The special recognition prize highlights seven companies with exemplary track records, each of these companies belonging to a different category.

Download 20180712_ForbesFutur40_EN_final.pdf

About Median Technologies

Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy®, our AI-powered software as medical device help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information:


Median Technologies

Emmanuelle Leygues
Head of Corporate Marketing and Financial Communications
+33 6 10 93 58 88

Actifin  (Investors)

Ghislaine Gasparetto
+33 6 21 10 49 24

Alizé RP  (Press)

Caroline Carmagnol
+33 6 64 18 99 59